Cytokinetics Inc (NASDAQ: CYTK) kicked off on Tuesday, up 2.02% from the previous trading day, before settling in for the closing price of $51.48. Over the past 52 weeks, CYTK has traded in a range of $30.68-$110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 12.30%. While this was happening, its average annual earnings per share was recorded 6.15%. With a float of $113.75 million, this company’s outstanding shares have now reached $117.66 million.
Let’s determine the extent of company efficiency that accounts for 423 employees. In terms of profitability, gross margin is -2886.73%, operating margin of -16148.37%, and the pretax margin is -17398.82%.
Cytokinetics Inc (CYTK) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 3.33%, while institutional ownership is 114.33%. The most recent insider transaction that took place on Nov 01 ’24, was worth 258,150. In this transaction President & CEO of this company sold 5,000 shares at a rate of $51.63, taking the stock ownership to the 397,456 shares. Before that another transaction happened on Nov 01 ’24, when Company’s Officer proposed sale 5,000 for $51.63, making the entire transaction worth $258,158.
Cytokinetics Inc (CYTK) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1.35 earnings per share (EPS), lower than consensus estimate (set at -0.74) by -0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Take a look at Cytokinetics Inc’s (CYTK) current performance indicators. Last quarter, stock had a quick ratio of 10.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1974.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.37, a number that is poised to hit -1.23 in the next quarter and is forecasted to reach -4.87 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Looking closely at Cytokinetics Inc (NASDAQ: CYTK), its last 5-days average volume was 0.86 million, which is a drop from its year-to-date volume of 2.08 million. As of the previous 9 days, the stock’s Stochastic %D was 36.65%. Additionally, its Average True Range was 1.67.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 18.34%, which indicates a significant decrease from 41.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.93% in the past 14 days, which was lower than the 33.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $54.09, while its 200-day Moving Average is $61.15. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $53.39. Second resistance stands at $54.25. The third major resistance level sits at $55.51. If the price goes on to break the first support level at $51.27, it is likely to go to the next support level at $50.01. Now, if the price goes above the second support level, the third support stands at $49.15.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
The company with the Market Capitalisation of 6.18 billion has total of 117,660K Shares Outstanding. Its annual sales at the moment are 7,530 K in contrast with the sum of -526,240 K annual income. Company’s last quarter sales were recorded 250 K and last quarter income was -143,320 K.
